Which has stronger valuation & earnings, REPL or LRMR?

Replimune Group is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$313.94M -$3.15 N/A Larimar Therapeutics N/A N/A -$165.67M -$1.95 N/A

Is REPL or LRMR more profitable?

Larimar Therapeutics' return on equity of -137.39% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -159.32% -90.84% Larimar Therapeutics N/A -137.39% -97.65%

Which has stronger earnings and valuation, LRMR or TYRA?

Tyra Biosciences is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$1.95 N/A Tyra Biosciences N/A N/A -$119.95M -$2.40 N/A

Is LRMR or TYRA more profitable?

Tyra Biosciences' return on equity of -46.39% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -137.39% -97.65% Tyra Biosciences N/A -46.39% -43.07%

Which has higher valuation and earnings, LRMR or TRAX?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$1.95 N/A First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A

Is LRMR or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -137.39% -97.65% First Tracks Biotherapeutics N/A N/A N/A

Which has better earnings and valuation, BCAX or LRMR?

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bicara Therapeutics N/A N/A -$137.95M -$3.10 N/A Larimar Therapeutics N/A N/A -$165.67M -$1.95 N/A

Is BCAX or LRMR more profitable?

Bicara Therapeutics' return on equity of -41.49% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bicara Therapeutics N/A -41.49% -38.59% Larimar Therapeutics N/A -137.39% -97.65%

Larimar Therapeutics (LRMR) Competitors

$2.67 -0.03 (-1.11%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.69 +0.02 (+0.60%)

As of 10/9/2026 07:53 PM Eastern

Compare

LRMR vs. REPL, MNKD, TYRA, TRAX, and BCAX

Should you buy Larimar Therapeutics stock or one of its competitors? Larimar Therapeutics's main competitors and comparable companies include Replimune Group (REPL), MannKind (MNKD), Tyra Biosciences (TYRA), First Tracks Biotherapeutics (TRAX), and Bicara Therapeutics (BCAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Larimar Therapeutics compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 5.4% of Replimune Group shares are held by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Replimune Group is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

Replimune Group currently has a consensus price target of $12.00, indicating a potential downside of 10.58%. Larimar Therapeutics has a consensus price target of $10.33, indicating a potential upside of 287.02%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Larimar Therapeutics' return on equity of -137.39% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-159.32%	-90.84%
Larimar Therapeutics	N/A	-137.39%	-97.65%

Replimune Group has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

In the previous week, Replimune Group had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 3 mentions for Replimune Group and 1 mentions for Larimar Therapeutics. Replimune Group's average media sentiment score of 0.41 beat Larimar Therapeutics' score of -1.00 indicating that Replimune Group is being referred to more favorably in the media.

Company	Overall Sentiment
Replimune Group	Neutral
Larimar Therapeutics	Negative

Summary

Larimar Therapeutics beats Replimune Group on 7 of the 13 factors compared between the two stocks.

How does Larimar Therapeutics compare to MannKind?

MannKind (NASDAQ:MNKD) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

MannKind has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

49.6% of MannKind shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Larimar Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	N/A	-6.31%
Larimar Therapeutics	N/A	-137.39%	-97.65%

MannKind has higher revenue and earnings than Larimar Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.03	$5.86M	-$0.13	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

MannKind currently has a consensus price target of $7.84, indicating a potential upside of 138.41%. Larimar Therapeutics has a consensus price target of $10.33, indicating a potential upside of 287.02%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, MannKind had 9 more articles in the media than Larimar Therapeutics. MarketBeat recorded 10 mentions for MannKind and 1 mentions for Larimar Therapeutics. MannKind's average media sentiment score of 0.53 beat Larimar Therapeutics' score of -1.00 indicating that MannKind is being referred to more favorably in the media.

Company	Overall Sentiment
MannKind	Positive
Larimar Therapeutics	Negative

Summary

MannKind beats Larimar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Tyra Biosciences?

Larimar Therapeutics (NASDAQ:LRMR) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Tyra Biosciences' return on equity of -46.39% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Tyra Biosciences	N/A	-46.39%	-43.07%

In the previous week, Tyra Biosciences had 3 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Tyra Biosciences and 1 mentions for Larimar Therapeutics. Tyra Biosciences' average media sentiment score of 0.13 beat Larimar Therapeutics' score of -1.00 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Larimar Therapeutics	Negative
Tyra Biosciences	Neutral

Tyra Biosciences is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Larimar Therapeutics currently has a consensus price target of $10.33, indicating a potential upside of 287.02%. Tyra Biosciences has a consensus price target of $47.20, indicating a potential upside of 136.71%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Larimar Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Larimar Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Summary

Tyra Biosciences beats Larimar Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Larimar Therapeutics compare to First Tracks Biotherapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

Larimar Therapeutics currently has a consensus price target of $10.33, indicating a potential upside of 287.02%. First Tracks Biotherapeutics has a consensus price target of $65.75, indicating a potential upside of 106.44%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Larimar Therapeutics is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

First Tracks Biotherapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
First Tracks Biotherapeutics	N/A	N/A	N/A

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 3 mentions for First Tracks Biotherapeutics and 1 mentions for Larimar Therapeutics. First Tracks Biotherapeutics' average media sentiment score of 0.83 beat Larimar Therapeutics' score of -1.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Larimar Therapeutics	Negative
First Tracks Biotherapeutics	Positive

Summary

Larimar Therapeutics and First Tracks Biotherapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Larimar Therapeutics compare to Bicara Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

91.9% of Larimar Therapeutics shares are held by institutional investors. 13.8% of Bicara Therapeutics shares are held by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bicara Therapeutics presently has a consensus price target of $32.64, suggesting a potential upside of 86.49%. Larimar Therapeutics has a consensus price target of $10.33, suggesting a potential upside of 287.02%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.75
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Bicara Therapeutics had 3 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Bicara Therapeutics and 1 mentions for Larimar Therapeutics. Bicara Therapeutics' average media sentiment score of 0.34 beat Larimar Therapeutics' score of -1.00 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicara Therapeutics	Neutral
Larimar Therapeutics	Negative

Bicara Therapeutics has a beta of -0.7, indicating that its stock price is 170% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

Bicara Therapeutics' return on equity of -41.49% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-41.49%	-38.59%
Larimar Therapeutics	N/A	-137.39%	-97.65%

Summary

Bicara Therapeutics beats Larimar Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Larimar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LRMR vs. The Competition

Export

Metric	Larimar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$280.48M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.36%
P/E Ratio	-1.37	13.42	274.15	26.16
Price / Sales	N/A	1,237.94	590.34	94.78
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	2.84	17.17	11.21	6.34
Net Income	-$165.67M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-9.80%	-1.33%	-0.90%	-1.41%
1 Month Performance	-30.65%	-8.44%	-4.44%	-3.48%
1 Year Performance	-38.76%	14.02%	6.96%	1.16%

Larimar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LRMR Larimar Therapeutics	2.215 of 5 stars	$2.67 -1.1%	$10.33 +287.0%	-41.3%	$280.48M	N/A	N/A	71	Negative News
REPL Replimune Group	1.2412 of 5 stars	$13.15 +0.6%	$12.00 -8.7%	+189.8%	$1.23B	N/A	N/A	465
MNKD MannKind	3.8891 of 5 stars	$3.82 +0.5%	$8.34 +118.4%	-36.0%	$1.22B	$348.97M	N/A	592	Analyst Forecast
TYRA Tyra Biosciences	3.3647 of 5 stars	$20.93 +2.4%	$46.89 +124.0%	+44.3%	$1.22B	N/A	N/A	87	Analyst Forecast
TRAX First Tracks Biotherapeutics	2.9363 of 5 stars	$32.99 -0.9%	$65.17 +97.5%	N/A	$1.19B	N/A	N/A	104	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LRMR) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Larimar Therapeutics (LRMR) Competitors

LRMR vs. REPL, MNKD, TYRA, TRAX, and BCAX

How does Larimar Therapeutics compare to Replimune Group?

Summary

How does Larimar Therapeutics compare to MannKind?

Summary

How does Larimar Therapeutics compare to Tyra Biosciences?

Summary

How does Larimar Therapeutics compare to First Tracks Biotherapeutics?

Summary

How does Larimar Therapeutics compare to Bicara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Larimar Therapeutics (LRMR) Competitors

LRMR vs. REPL, MNKD, TYRA, TRAX, and BCAX

How does Larimar Therapeutics compare to Replimune Group?

Do institutionals & insiders believe in REPL or LRMR?

Which has stronger valuation & earnings, REPL or LRMR?

Do analysts prefer REPL or LRMR?

Is REPL or LRMR more profitable?

Which has more risk and volatility, REPL or LRMR?

Does the media prefer REPL or LRMR?

Summary

How does Larimar Therapeutics compare to MannKind?

Which has more risk and volatility, MNKD or LRMR?

Do insiders and institutionals have more ownership in MNKD or LRMR?

Is MNKD or LRMR more profitable?

Which has preferable earnings and valuation, MNKD or LRMR?

Do analysts prefer MNKD or LRMR?

Does the media refer more to MNKD or LRMR?

Summary

How does Larimar Therapeutics compare to Tyra Biosciences?

Is LRMR or TYRA more profitable?

Does the media prefer LRMR or TYRA?

Which has stronger earnings and valuation, LRMR or TYRA?

Do analysts rate LRMR or TYRA?

Do insiders & institutionals have more ownership in LRMR or TYRA?

Which has more risk & volatility, LRMR or TYRA?

Summary

How does Larimar Therapeutics compare to First Tracks Biotherapeutics?

Do institutionals & insiders believe in LRMR or TRAX?

Which has higher valuation and earnings, LRMR or TRAX?

Do analysts recommend LRMR or TRAX?

Is LRMR or TRAX more profitable?

Does the media prefer LRMR or TRAX?

Summary

How does Larimar Therapeutics compare to Bicara Therapeutics?

Do insiders and institutionals hold more shares of BCAX or LRMR?

Do analysts prefer BCAX or LRMR?

Does the media refer more to BCAX or LRMR?

Which has more risk & volatility, BCAX or LRMR?

Which has better earnings and valuation, BCAX or LRMR?

Is BCAX or LRMR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools